Liver Fibrosis Treatment Market Snapshot (2023 to 2033)
The global liver fibrosis treatment market is expected to surpass an impressive valuation of US$ 16.43 billion in 2022 and is projected to exhibit a CAGR of 11% from 2022 to 2033. The primary factors of death and morbidity in individuals with liver cirrhosis are liver fibrosis and, in specific, cirrhosis. Their intervention or reversal has emerged as critical access points in clinical trials involving innovative liver-specific stimulants.
In persistent hepatitis B and C, significant advancements have been made with treatments that effectively address the consequence of fundamental liver damage. In the proportion of patients, extremely effective suppressive therapy can control strategies or even generate reversal, but this treatment remains elusive for the vast bulk of liver patients suffering from advanced alcoholic or nonalcoholic steatohepatitis, and genetic or immune deficiency liver failure.
Implementation for patients with liver fibrosis and personalized treatment is inextricably linked to the emergence of noninvasive fibrosis, fibrogenesis, and fibrosis biomarkers, which will continue to lead the industry. Cirrhosis is the 12th primary factor of death in the United States. Latest research has shown that liver fibrosis is a continual process and that initial cirrhosis may be recoverable. As a result, the treatment for liver fibrosis is expected to grow significantly over the next decades. Although liver biopsy is still the fundamental basis, transient elastography has become increasingly widely available and is quickly replacing biopsy as the preferred option for liver fibrosis staging which is contributing to the market expansion.
Furthermore, rising cancer cases, including liver cancer, are anticipated to propel the expansion of the global chronic liver disease therapeutic industry, contributing to market growth. For instance, the American Cancer Society estimates that 41,260 suspected cases of primary liver cancer were diagnosed in the United States in 2022 (28,600 in men and 12,660 in women).
Rising the number of various forms of chronic liver diseases is driving the market growth. For instance, Primary Sclerosing Cholangitis (PSC) is a chronic illness in which the bile ducts inside and outside the liver get to be sore and disfigured, ultimately narrowing and blocking, and causing liver damage. Based on the National Institute of Health, nonalcoholic fatty liver disease (NAFLD) represents the most prevalent liver disease, accounting for 25% of all cases worldwide. NAFLD and its variant, nonalcoholic steatohepatitis, influence 30% and 5% of the people in the United States, respectively. Therefore, treatment for liver fibrosis is expected to grow significantly in this country.
Hepatitis C therapeutics are becoming more widely used among healthcare professionals in the United States, and a growing number of patients are receiving them. This, integrated with a robust R&D pipeline and the introduction of novel medicines in the United States, is accelerating the expansion of the hepatitis C treatment marketplace in North America. For instance, in April 2019, the US Food and Drug Administration approved Mavyret by AbbVie as the first-ever treatment affirmed for pediatric Hepatitis C patients of all genotypes. As a result of these factors, the Liver Fibrosis Treatment Market is expected to grow in the coming decades.
The high incidence of Nonalcoholic steatohepatitis (NASH) also affects the population, fueling the market growth. NASH affects approximately 3% to 6% of the US inhabitants, and the pervasiveness is rising. Although there are several noninvasive screening and rating systems available to characterize NAFLD and NASH, liver biopsy is the only acceptable form for diagnosing NASH. Presently, the US Food and Drug Administration has not approved any NASH-specific therapies.
Data Points
Key Statistics
Expected Market Value (2022)
US$ 16.43 billion
Anticipated Forecast Value (2033)
US$ 46.65 billion
Projected Growth Rate (2022 to 2033)
11% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Liver Fibrosis Treatment Demand Analysis vs. Forecast 2022 to 2033
The COVID-19 pandemic had an adverse effect on the global liver fibrosis therapeutics market, as the demand for medications used in liver rehabilitation decreased. Based on the National Center for Biotechnology Information, COVID-19 therapy in January 2020 involves discussing and parenterally administered agents, antivirals, immunomodulatory medicines, anti-cytokines, monoclonal antibodies, and miscellaneous agents. As a result, drugs demonstrated for use in other disease conditions have been produced in smaller quantities than those used in COVID-19 treatment. From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3%.
The rise in the prevalence of adverse outcomes such as patients with hepatitis B or C virus infection, a suppressed immune system owing to co-infection with human immunodeficiency virus (HIV), and the usage of immunosuppressive medicines after a liver transplant are poised to drive growth in the liver fibrosis treatment market over the forecast period. For instance, as per World Health Organization data released in 2022, 296 million individuals were estimated to be residing with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. Hepatitis B caused an estimated 820 000 deaths in 2019, the majority of which were caused by cirrhosis and hepatocellular carcinoma.
Which are Some Prominent Drivers of the Liver Fibrosis Treatment Market?
Funding Approaches by multiple private research organizations to Drive Market
The increased research carried out by several private research organizations to develop treatments for liver fibrosis and other fatty liver diseases are anticipated to increase growth in the liver fibrosis treatment market. For instance, in August 2018, Virginia Tech's College of Science and the University of Virginia's Department of Pharmacology garnered US$400,000 in funding from the Virginia Biosciences Health Research Corporation (VBHRC), with Continuum Biosciences, Inc. matching funds. This grant, combined with matching funds, would assist scientists in creating drugs to treat nonalcoholic steatohepatitis (NASH).
Research and studies to evolve novel treatment therapies in liver fibrosis disease drive market growth
Expanding pre-clinical and clinical studies and development by prominent stakeholders to establish innovative treatment options in the liver fibrosis regime are predicted to propel the worldwide liver fibrosis treatment's future growth. For instance, the US Food and Drug Administration permitted Orphan Drug Designation to PTG-300, a subcutaneous injectable evolved by Protagonist Therapeutics, Inc., in March 2018. The PTG-300 is presently in a medical study for the treatment of beta-thalassemia and can also be employed to cure liver fibrosis.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Projected to be Faced by the Market?
High Costs to Hinder Market Growth
The massive cost necessary for drug assessment of the liver disease therapeutic process is one of the key factors impeding the expansion of the global liver fibrosis treatment market. According to the Centers for Disease Analysis, the United States invests $5 billion per year on disease-related healthcare costs like chemotherapy, transplants, screening, and hospitalizations.
Region-Wise Insights
What Makes North America the Largest Market for Liver Fibrosis Treatment?
The accessibility of a variety of Innovative Drug Molecules drive Asia Pacific market
Owing to the availability of a variety of novel drug molecules to improve the treatment process and technological development in rehabilitation in this region, North America leads the liver fibrosis market. Furthermore, surging medical spending and the emergence of major important players will speed up the market's pace of growth in this region. The mortality rate from liver diseases has increased, as has the occurrence of liver cancer.
Non-alcoholic fatty liver disorder (NAFLD) affects approximately 20% of Canadians, based on the Canadian Liver Foundation. Obesity is the primary factor of fatty liver disease in Canada. In 2018, nearly 30% of Canadians aged 18 and up reported being overweight or obese based on their height and weight.
Why is Asia Pacific Considered a Lucrative Region for the Liver Fibrosis Treatment Market?
Increasing Prevalence of Liver Fibrosis is Spurring Demand for Liver Fibrosis Treatment
Asia Pacific is predicted to expand during the forthcoming years owing to the rising incidence of liver fibrosis in this region. Moreover, the advancement of medical infrastructure and soaring regulatory reforms will enhance the industry's pace of growth in this region. During the projected period, the Asia Pacific market is projected to show the highest CAGR of 11.1%.
There is a growing patient pool of hepatitis C patients in developing nations like China, India, and other South-East Asian countries. Nevertheless, the patient population is dependent on the various governments for subsidized drugs, and earnings contribution is lesser; moreover, due to such aspects, the market in the Asia Pacific is growing rapidly.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
By End-User, Which Segment is Projected to Lead the Market?
Hospital Segment is Estimated to Hold the Largest Share
Based on end user, the global liver fibrosis treatment market is segmented into hospital, and Specialty Clinics. The hospital segment held the largest share of the market in 2021. Moreover, the same segment is expected to register the highest CAGR from 2022 to 2033.
Which Treatment Type Segment to Grow Rapidly?
Hepatotropic drug segment led the market in historical period
With a market share of 29.5% in 2021, the hepatotropic drug segment led the market. This increase is attributed to increased awareness of new drugs. Furthermore, hepatitis is a medical condition that primarily affects the liver, eventually contaminating the digestion process and the brain. HCV, HBV, and HAV are the three major types of hepatitis conditions. HCV is a major public health problem in which the liver becomes inflamed as a result of infection. As a result, this segment is expected to grow rapidly.
Start Ups offering Liver Fibrosis Treatment
Beijing Continent Pharmaceutical Co, Ltd., a pharmacological firm started in 2002, completed an effective Phase II clinical trial for Hydronidone capsules in December 2021 and was enhanced to a Phase 3 clinical trial in January 2022. The phase 3 clinical trial experiments for Hydronidone capsules are still continuing and are anticipated to be completed in June 2024.
HepC is a developer of antibacterial pharmacologic products that was established in 2005. IBDV, a non-pathogenic double-stranded RNA virus, is used by the organization. As its foremost vector scheme, this virus behaves as an expert inducer of antiviral gene reactions. It is developing HC001 to cure chronic viral hepatitis caused by HBV and HCV infections.
Market Competition
Key players in the Liver Fibrosis Treatment market are Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., Inventiva Pharma, Pharmaxis Limited.
In March 2019, Gilead Sciences Inc. launched the HepConnect Program to Reduce Hepatitis C Infections in Greater Appalachia.
It was disclosed in December 2020 that Aligos Therapeutics Inc. will collaborate with Merck & Co. Inc. to create a therapy for liver fibrosis treatment.
Report Scope
Report Attribute
Details
Market Value in 2022
US$ 2.5 billion
Market Value in 2033
US$ 46.65 billion
Growth Rate
CAGR of 11% from 2022 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2022 to 2033
Quantitative Units
Revenue in US$ Billion and CAGR from 2022 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
Treatment Type
Condition
End User
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Key Countries Profiled
USA
Canada
Brazil
Mexico
Mexico
Germany
United Kingdom
France
Spain
Italy
India
Malaysia
Singapore
Thailand
China
Japan
South Korea
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Gilead Sciences, Inc.
Merck & Co., Inc.
Bristol-Myers Squibb
Johnson and Johnson
Novartis AG
Vertex Pharmaceuticals Incorporated
Pfizer Inc.
FibroGen, Inc.
Inventiva Pharma
Pharmaxis Limited
Customization
Available Upon Request
Key Segments Profiled in the Liver Fibrosis Treatment Industry Survey
How Big will be the Liver Fibrosis Treatment Market by 2033?
The market is estimated to reach US$ 46.65 billion by 2033.
Who are the Key Liver Fibrosis Treatment Market Players?
Gilead Sciences, Inc., Merck & Co., Inc., and Bristol-Myers Squibb are key market players.
What is the Growth Forecast for the Liver Fibrosis Treatment Market?
The market is forecasted to register a CAGR of 11% through 2033.
What is Asia Pacific's Expected Growth Rate through 2033?
Asia Pacific is likely to expand at a CAGR of 11.1% through 2033.
Which End-use Industry Held a Significant Share in the Market?
The hospital sector held a significant share in 2021.
Table of Content
1. Executive Summary | Liver Fibrosis Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033
5.3.1. Peroxisome Proliferator-activated Receptors (PPAR)-alpha Agonist
5.3.2. ACE Inhibitors
5.3.3. Hepatotropic Drug
5.3.4. Others
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Condition
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Condition, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Condition, 2023 to 2033
6.3.1. Chronic Liver Diseases
6.3.2. Hepatitis C
6.3.3. Nonalcoholic Steatohepatitis
6.4. Y-o-Y Growth Trend Analysis By Condition, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Condition, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User , 2023 to 2033
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Others
7.4. Y-o-Y Growth Trend Analysis By End User , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Treatment Type
9.2.3. By Condition
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment Type
9.3.3. By Condition
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Treatment Type
10.2.3. By Condition
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment Type
10.3.3. By Condition
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Treatment Type
11.2.3. By Condition
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By Condition
11.3.4. By End User
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Treatment Type
12.2.3. By Condition
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By Condition
12.3.4. By End User
12.4. Key Takeaways
13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Treatment Type
13.2.3. By Condition
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By Condition
13.3.4. By End User
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Treatment Type
14.1.2.2. By Condition
14.1.2.3. By End User
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Treatment Type
14.2.2.2. By Condition
14.2.2.3. By End User
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Treatment Type
14.3.2.2. By Condition
14.3.2.3. By End User
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Treatment Type
14.4.2.2. By Condition
14.4.2.3. By End User
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Treatment Type
14.5.2.2. By Condition
14.5.2.3. By End User
14.6. United Kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Treatment Type
14.6.2.2. By Condition
14.6.2.3. By End User
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Treatment Type
14.7.2.2. By Condition
14.7.2.3. By End User
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Treatment Type
14.8.2.2. By Condition
14.8.2.3. By End User
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Treatment Type
14.9.2.2. By Condition
14.9.2.3. By End User
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Treatment Type
14.10.2.2. By Condition
14.10.2.3. By End User
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Treatment Type
14.11.2.2. By Condition
14.11.2.3. By End User
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Treatment Type
14.12.2.2. By Condition
14.12.2.3. By End User
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Treatment Type
14.13.2.2. By Condition
14.13.2.3. By End User
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Treatment Type
14.14.2.2. By Condition
14.14.2.3. By End User
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Treatment Type
14.15.2.2. By Condition
14.15.2.3. By End User
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Treatment Type
14.16.2.2. By Condition
14.16.2.3. By End User
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Treatment Type
14.17.2.2. By Condition
14.17.2.3. By End User
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Treatment Type
14.18.2.2. By Condition
14.18.2.3. By End User
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Treatment Type
14.19.2.2. By Condition
14.19.2.3. By End User
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Treatment Type
14.20.2.2. By Condition
14.20.2.3. By End User
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Treatment Type
15.3.3. By Condition
15.3.4. By End User
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Gilead Sciences, Inc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Merck & Co., Inc.
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Bristol-Myers Squibb
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Johnson and Johnson
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Novartis AG
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Vertex Pharmaceuticals Incorporated
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Pfizer Inc.
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. FibroGen, Inc.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Inventiva Pharma
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Pharmaxis Limited.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Condition, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by End User , 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Condition, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by End User , 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Condition, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by End User , 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Condition, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by End User , 2018 to 2033
Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Asia Pacific Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 19: Asia Pacific Market Value (US$ Million) Forecast by Condition, 2018 to 2033
Table 20: Asia Pacific Market Value (US$ Million) Forecast by End User , 2018 to 2033
Table 21: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: MEA Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 23: MEA Market Value (US$ Million) Forecast by Condition, 2018 to 2033
Table 24: MEA Market Value (US$ Million) Forecast by End User , 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Condition, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by End User , 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Condition, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by End User , 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End User , 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033
Figure 17: Global Market Attractiveness by Treatment Type, 2023 to 2033
Figure 18: Global Market Attractiveness by Condition, 2023 to 2033
Figure 19: Global Market Attractiveness by End User , 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Condition, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by End User , 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Condition, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by End User , 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End User , 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033
Figure 37: North America Market Attractiveness by Treatment Type, 2023 to 2033
Figure 38: North America Market Attractiveness by Condition, 2023 to 2033
Figure 39: North America Market Attractiveness by End User , 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Condition, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by End User , 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Condition, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by End User , 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User , 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033
Figure 57: Latin America Market Attractiveness by Treatment Type, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Condition, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End User , 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Condition, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by End User , 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Condition, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by End User , 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by End User , 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033
Figure 77: Europe Market Attractiveness by Treatment Type, 2023 to 2033
Figure 78: Europe Market Attractiveness by Condition, 2023 to 2033
Figure 79: Europe Market Attractiveness by End User , 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Asia Pacific Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 82: Asia Pacific Market Value (US$ Million) by Condition, 2023 to 2033
Figure 83: Asia Pacific Market Value (US$ Million) by End User , 2023 to 2033
Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Condition, 2018 to 2033
Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033
Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033
Figure 94: Asia Pacific Market Value (US$ Million) Analysis by End User , 2018 to 2033
Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by End User , 2023 to 2033
Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033
Figure 97: Asia Pacific Market Attractiveness by Treatment Type, 2023 to 2033
Figure 98: Asia Pacific Market Attractiveness by Condition, 2023 to 2033
Figure 99: Asia Pacific Market Attractiveness by End User , 2023 to 2033
Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 101: MEA Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 102: MEA Market Value (US$ Million) by Condition, 2023 to 2033
Figure 103: MEA Market Value (US$ Million) by End User , 2023 to 2033
Figure 104: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: MEA Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 109: MEA Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 110: MEA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 111: MEA Market Value (US$ Million) Analysis by Condition, 2018 to 2033
Figure 112: MEA Market Value Share (%) and BPS Analysis by Condition, 2023 to 2033
Figure 113: MEA Market Y-o-Y Growth (%) Projections by Condition, 2023 to 2033
Figure 114: MEA Market Value (US$ Million) Analysis by End User , 2018 to 2033
Figure 115: MEA Market Value Share (%) and BPS Analysis by End User , 2023 to 2033
Figure 116: MEA Market Y-o-Y Growth (%) Projections by End User , 2023 to 2033
Figure 117: MEA Market Attractiveness by Treatment Type, 2023 to 2033
Figure 118: MEA Market Attractiveness by Condition, 2023 to 2033
Figure 119: MEA Market Attractiveness by End User , 2023 to 2033
Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
